Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study Evaluating the Safety, Pharmacokinetics, and Initial Efficacy of a GPC3-targeted Chimeric Antigen Receptor Autologous T Cell Injection (OriC902) in GPC3-positive Advanced Hepatocellular Carcinoma (HCC) Subjects

NCT06891742 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT06891742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06891742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study Evaluating the Safety, Pharmacokinetics, and Initial Efficacy of a GPC3-targeted Chimeric Antigen Receptor Autologous T Cell Injection (OriC902) in GPC3-positive Advanced Hepatocellular Carcinoma (HCC) Subjects
Lead sponsor
Peking University
Phase
Phase 1
Overall status
Recruiting
Start date
February 24, 2025
Completion date
March 31, 2028
Enrollment
44 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hcc